Stresson is developed by Jagiellonian University.

What development phase is Stresson in?

Stresson is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Stresson

Jagiellonian University · FDA-approved active Small molecule Quality 2/100

Stresson, marketed by Jagiellonian University, holds a niche position in its therapeutic area with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging the credibility of an academic institution. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Stresson
Sponsor	Jagiellonian University
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Impact of Immunostimulating Nutrition on the Outcome of Surgery (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Stresson CI brief — competitive landscape report
Stresson updates RSS · CI watch RSS
Jagiellonian University portfolio CI